Endovascular therapy for mild ischemic stroke with large vessel occlusion

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of endovascular therapy (EVT) combined with best medical management for patients experiencing a mild ischemic stroke due to large vessel occlusion (LVO) who have shown early neurological deterioration. Approximately 272 patients aged 18 and older will be enrolled and randomized into two groups: one receiving only medical management and the other receiving EVT in addition to medical management. The study aims to determine if EVT can improve outcomes in patients who present with a minor stroke and experience symptom progression more than 24 hours after the onset. The primary endpoint is the rate of favorable outcomes measured by the modified Rankin scale at 90 days post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

General Inclusion Criteria：

* Age ≥ 18 years；
* Presenting with symptoms consistent with an AIS and the initial NIHSS score \<6 points；
* Symptom progression within 7 days of first onset；
* Randomization can be finished \> 24 hours of stroke onset (stroke onset time is defined as last known well time)；
* Symptom progression to randomization time ≤ 24 hours；
* NIHSS score before randomization ≥ 6 points；
* Informed consent signed.

Specific Neuroimaging Inclusion Criteria

* CTA or MRA proved occlusion of Internal Carotid Artery (ICA) terminal or M1 segment of Middle Cerebral Artery;
* The progression of symptoms is caused by the recurrence of cerebrovascular diseases in the same vascular region, or the pathogenesis is caused by reduced blood flow perfusion;
* NCCT ASPECTS before randomization ≥ 6
* CTP or MRP assessment shows low perfusion in the target vessel area, and meets the following criteria: core infarction volume is less than 50ml, mismatch rate is greater than or equal to 1.8, and mismatch volume is greater than 15ml.

Exclusion Criteria:

* Pre-stroke mRS score \>1;
* Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes;
* The target vessel may have factors that may prevent it from completing endovascular treatment, such as a diameter less than 1.5mm, a tortuous vascular pathway, difficulty in reaching the target position with instruments, or difficulty in recovery;
* Severe stenosis or occlusion of multiple blood vessels;
* Combined with untreated intracranial aneurysms, intracranial tumors (excluding small meningiomas), or intracranial vascular malformations;
* Intracranial hemorrhage within 6 months, including cerebral parenchymal hemorrhage, ventricular hemorrhage, and subarachnoid hemorrhage;
* Have had gastrointestinal or urinary system bleeding, acute myocardial infarction, traumatic brain injury, or undergone major surgical procedures within the past month;
* Known hemorrhagic tendency (including but not limited to): Baseline platelet count \<40×109/L; on anticoagulant therapy with warfarin and International Normalized Ratio (INR) \> 2 (Patients with no history or suspected coagulopathy do not need to wait for laboratory results of INR or APTT prior to enrollment) Severe heart, liver, kidney function damage or other severe late stage diseases of the system;
* Known allergies to treatment related drugs such as iodine contrast agents, etc; Known severe allergy (more than a rash) to contrast media uncontrolled by medications;
* Refractory hypertension (defined as persistent systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg);
* Uncontrolled blood sugar abnormalities (less than 2.8mmol/l or greater than 22.2mmol/l);
* Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test;
* The expected survival time is less than 1 year (such as complicated with malignant tumor, serious heart and lung diseases, etc.)
* Participation in other interventional randomized clinical trials that may confound outcome assessment of the trial
* Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (such as inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders)

Where it's running

• Fuyang People's Hospital
  Fuyang, Anhui, China Recruiting
• First Affiliated Hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting
• The first Hospital of Anhui University Of Science & Technology
  Huainan, Anhui, China Recruiting
• Huangshan City People's Hospital
  Huangshan City, Anhui, China Recruiting
• Wan Bei General Hospital of Wanbei Coal power Group
  Suzhou, Anhui, China Recruiting
• The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College
  Wuhu, Anhui, China Recruiting

Study contacts

• Principal investigator: Zhiming Zhou, PhD — The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College
• Study coordinator: Zhiming Zhou, PhD
• Email: neuro_depar@hotmail.com
• Phone: (++)86-(+)-553-5739543

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Paired VNS: How the Brain and Pupils Respond in Stroke Patients

  This study tests real-time physiologic responses to paired VNS in adults with chronic motor impairment after ischemic stroke to help tailor dosing.

  Recruiting MGH Institute of Health Professions · Boston, Massachusetts · NCT07922200

• NeuroAiD test in mild to moderate ischemic stroke patients

  This study tests whether adding MLC901 (NeuroAiD II) to standard stroke care helps adults who recently had an ischemic stroke recover better than standard care alone.

  Recruiting Phase 4 EVD Pharmacy and Medical Company Limited · Ho Chi Minh City · NCT07828210

• Using IMPROVE to guide carotid revascularisation decisions

  This trial tests whether using the IMPROVE MRI-based score to select patients for carotid revascularisation is as good as standard care based mainly on stenosis degree, among people who have had a recent stroke or TIA due to carotid disease.

  Recruiting Maastricht University Medical Center · Arnhem, Gelderland and 9 other locations · NCT07556887

• High-intensity interval versus moderate continuous exercise for stroke-related muscle loss

  This will test whether high-intensity interval training (HIIT) or moderate-intensity continuous training (MCIT) better helps people 1–6 months after an ischemic stroke who have muscle loss regain muscle mass, strength, walking ability, and quality of life.

  Recruiting Fenerbahce University · Istanbul, Ataşehir · NCT07456956

• Test of adding a very low-dose edoxaban to standard antiplatelet therapy to prevent another stroke in adults 75 and older

  This trial tests whether adding a tiny amount of edoxaban to aspirin or clopidogrel can better prevent a second stroke in people aged 75+ who recently had an ischemic stroke.

  Recruiting Phase 3 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07454707

• HR-MRI–Directed Tirofiban Therapy for Late-Window ICAS-LAA Stroke

  We’re testing whether tirofiban plus dual antiplatelet therapy, guided by high-resolution MRI of the brain’s blood vessels, can help people with intracranial large-artery atherosclerosis strokes that begin more than 24 hours after onset.

  Recruiting Phase 3 Weifang Medical University · Weifang, China/Shandong Province · NCT07379190

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.